The disclosure provides a new source of peripheral blood naive/memory stem cells (i.e. (TN)/TSCM/TCM) T-cells with enhanced reconstitution potential and/or longer life spans. It discloses that this particular subset of T-cells can be mobilized by administration of at least one mobilizer in combination with at least one E-Seiectin inhibitor.